SSA
SMMT icon

Schonfeld Strategic Advisors’s Summit Therapeutics SMMT Stock Holding History

Schonfeld Strategic Advisors’s Portfolio SMMT Stock Details SMMT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.33M Buy
91,557
+69,052
+307% +$1.22M ﹤0.01% 1304
2026
Q1 		$427K Sell
22,505
-4,799
-18% -$77.6K ﹤0.01% 1452
2025
Q4 		$478K Buy
+27,304
New +$514K ﹤0.01% 1412
2024
Q4 		– Sell
-56,024
Closed -$1.23M – 2357
2024
Q3 		$1.23M Buy
56,024
+34,105
+156% +$477K 0.01% 1096
2024
Q2 		$171K Buy
+21,919
New +$118K ﹤0.01% 1829
2023
Q2 		– Sell
-47,617
Closed -$83.3K – 2469
2023
Q1 		$83.3K Buy
+47,617
New +$130K ﹤0.01% 1722

Other funds holding SMMT

BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return

Schonfeld Strategic Advisors's SMMT Position: Q2 2026 in Review

Schonfeld Strategic Advisors increased its Summit Therapeutics (SMMT) stake by 307% in Q2 2026, buying an estimated $1.22M and bringing the position to 91,557 shares worth $1.33M. The position accounts for ﹤0.01% of the portfolio, ranked #1304.

Schonfeld Strategic Advisors first reported a position in SMMT in Q1 2023 and has held it in 6 quarters since. 242 funds tracked by Wall St. Rank hold SMMT as of Q2 2026.

  • Schonfeld Strategic Advisors held 91,557 shares of Summit Therapeutics worth $1.33M as of Q2 2026.
  • Schonfeld Strategic Advisors bought 69,052 Summit Therapeutics shares in Q2 2026, an estimated $1.22M.
  • Summit Therapeutics made up ﹤0.01% of Schonfeld Strategic Advisors's portfolio in Q2 2026, its #1304 holding.
  • Schonfeld Strategic Advisors first reported a position in Summit Therapeutics in Q1 2023 and has held it in 6 quarters since.
  • 242 funds tracked by Wall St. Rank held Summit Therapeutics as of Q2 2026.

Based on Schonfeld Strategic Advisors's 13F filing for Q2 2026, filed 14 Aug 2026.